MiNK Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
MiNK Therapeutics, Inc. (INKT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 25.28 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-13
- MiNK Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 0.00 shares, a 100.00% decline year-over-year.
- MiNK Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 25.28K shares, a 138.91% increase year-over-year.
- MiNK Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 8.81K shares.
- MiNK Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 790.00 shares, a 86.34% decline year-over-year.
- MiNK Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 23.86K shares, a 333.39% increase from fiscal 2024.
- MiNK Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 5.50K shares, a 91.10% decline from fiscal 2023.
- MiNK Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 61.88K shares, a 78.32% decline from fiscal 2022.
- MiNK Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 285.46K shares, a 624.04% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | 25.28K shares 10-Q · filed 2026-08-13 | 34.09K shares derived: sum of 3 quarters · filed 2026-08-13 | 34.88K shares derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | 25.28K shares 10-Q · filed 2026-05-15 | 34.09K shares derived: sum of 2 quarters · filed 2026-05-15 | 34.88K shares derived: sum of 3 quarters · filed 2026-05-15 | 38.55K shares derived: sum of 4 quarters · filed 2026-05-15 |
| 2025-12-31 | 8.81K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | 9.60K shares derived: sum of 2 quarters · filed 2026-03-31 | 13.28K shares derived: sum of 3 quarters · filed 2026-03-31 | 23.86K shares 10-K · filed 2026-03-31 |
| 2025-09-30 | 790.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | 4.47K shares derived: sum of 2 quarters · filed 2025-11-14 | 15.05K shares 10-Q · filed 2025-11-14 | -32.05K shares derived: sum of 4 quarters · filed 2025-11-14 |
| 2025-06-30 | 3.68K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | 14.26K shares 10-Q · filed 2025-08-14 | -32.84K shares derived: sum of 3 quarters · filed 2025-08-14 | -27.06K shares derived: sum of 4 quarters · filed 2025-08-14 |
| 2025-03-31 | 10.58K shares 10-Q · filed 2025-05-15 | -36.52K shares derived: sum of 2 quarters · filed 2025-05-15 | -30.73K shares derived: sum of 3 quarters · filed 2025-05-15 | -14.18K shares derived: sum of 4 quarters · filed 2025-05-15 |
| 2024-12-31 | -47.10K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | -41.31K shares derived: sum of 2 quarters · filed 2025-03-18 | -24.76K shares derived: sum of 3 quarters · filed 2025-03-18 | 5.50K shares 10-K · filed 2025-03-18 |
| 2024-09-30 | 5.78K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | 22.34K shares derived: sum of 2 quarters · filed 2024-11-14 | 52.60K shares 10-Q · filed 2024-11-14 | 54.49K shares derived: sum of 4 quarters · filed 2024-11-14 |
| 2024-06-30 | 16.56K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | 46.82K shares 10-Q · filed 2024-08-13 | 48.71K shares derived: sum of 3 quarters · filed 2024-08-13 | 106.38K shares derived: sum of 4 quarters · filed 2024-08-13 |
| 2024-03-31 | 30.26K shares 10-Q · filed 2024-05-14 | 32.15K shares derived: sum of 2 quarters · filed 2024-05-14 | 89.83K shares derived: sum of 3 quarters · filed 2024-05-14 | |
| 2023-12-31 | 1.89K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | 59.57K shares derived: sum of 2 quarters · filed 2024-03-21 | 61.88K shares 10-K · filed 2024-03-21 | |
| 2023-09-30 | 57.68K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | 59.99K shares 10-Q · filed 2023-11-14 | ||
| 2023-06-30 | 2.32K shares 10-Q · filed 2023-08-10 | |||
| 2022-12-31 | 90.89K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | 114.20K shares derived: sum of 2 quarters · filed 2023-03-24 | 285.46K shares 10-K · filed 2023-03-24 | |
| 2022-09-30 | 23.31K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | 194.57K shares 10-Q · filed 2022-11-03 | ||
| 2022-06-30 | 171.26K shares 10-Q · filed 2022-08-15 | |||
| 2021-12-31 | 39.43K shares 10-K · filed 2022-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |